DIFFUSE LARGE B-CELL LYMPHOMA REFRACTORY

This adverse event was reported 342 times

These drugs are most commonly taken by patients reporting DIFFUSE LARGE B-CELL LYMPHOMA REFRACTORY:

# Drug Count
0 RITUXIMAB 188
1 CYCLOPHOSPHAMIDE 171
2 DOXORUBICIN 149
3 ETOPOSIDE 127
4 PREDNISONE 124
5 CISPLATIN 116
6 DEXAMETHASONE 107
7 DEXAMETHASONE 1.5 MG 106
8 CYTARABINE 104
9 DOXORUBICIN HYDROCHLORIDE 74
See all common drugs associated with DIFFUSE LARGE B-CELL LYMPHOMA REFRACTORY

DIFFUSE LARGE B-CELL LYMPHOMA REFRACTORY is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 POLATUZUMAB VEDOTIN 53 0.0434
1 HYALURONIDASE (HUMAN RECOMBINANT) 1 0.0106
2 SELINEXOR 26 0.0085
3 CASPOFUNGIN ACETATE 32 0.0085
4 RITUXIMAB AND HYALURONIDASE 2 0.0073
5 IFOSFAMIDE 73 0.0060
6 ALBUMIN HUMAN 9 0.0047
7 DAPTOMYCIN 33 0.0034
8 DOXORUBICIN 149 0.0032
9 VINCRISTINE SULFATE 55 0.0031
See all drugs enriched for association with DIFFUSE LARGE B-CELL LYMPHOMA REFRACTORY

DIFFUSE LARGE B-CELL LYMPHOMA REFRACTORY is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
0 Endoglycosidase [EPC] 8 0.0071
1 Lipopeptide Antibacterial [EPC] 33 0.0034
2 Topoisomerase Inhibitor [EPC] 127 0.0029
3 CD20-directed Cytolytic Antibody [EPC] 193 0.0013
4 Alkylating Drug [EPC] 186 0.0012
5 Platinum-based Drug [EPC] 177 0.0012
6 CD30-directed Immunoconjugate [EPC] 4 0.0008
7 Nucleoside Metabolic Inhibitor [EPC] 140 0.0008
8 Aldosterone Antagonist [EPC] 34 0.0003
9 Vitamin K [EPC] 2 0.0003
See all drug classes enriched for association with DIFFUSE LARGE B-CELL LYMPHOMA REFRACTORY